Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Graviton Bioscience B V currently faces 1 pending office action located in the Biotechnology & Pharmaceuticals technology area. This 1 pending office action involves 1 distinct examiner and 1 distinct art unit, reflecting a streamlined prosecution profile. In the complex field of Biotechnology & Pharmaceuticals, having 1 pending office action allows for a highly targeted legal strategy. The practitioner can dedicate full attention to the specific nuances of the 1 distinct art unit, ensuring that the technical arguments are perfectly aligned with the examiner's specialized knowledge and the current standards of the office.
The busiest examiner, OTTON, ALICIA L, is currently handling 1 busiest examiner pending action. This 1 busiest examiner pending action constitutes the whole of the pending workload for Graviton Bioscience B V at this time. Consequently, the prosecution outcome depends entirely on the dialogue with OTTON, ALICIA L. Practitioners should analyze the past behavior of this 1 distinct examiner to anticipate potential hurdles. This focused engagement within the Biotechnology & Pharmaceuticals technology area minimizes the risk of conflicting examiner requirements that often arise in larger, more distributed patent portfolios.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OTTON, ALICIA L | 1 | 65.0% | +9.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18547257 | ROCK2 INHIBITOR FOR THE TREATMENT OF VIRAL INFECTION | OTTON, ALICIA L | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18547257 | ROCK2 INHIBITOR FOR THE TREATMENT OF VIRAL INFECTION | OTTON, ALICIA L | 1699 | §103§112 | Non-Final OA | — | Pending | Aug 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGraviton Bioscience B V has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alicia L Otton has the most, with 1 of Graviton Bioscience B V's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
